COYA Latest Press Releases

-- September 15, 2026 --

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS Business Wire 8:00 AM

-- September 8, 2026 --

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation Business Wire 8:00 AM

-- June 18, 2026 --

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting Business Wire 8:00 AM

-- June 15, 2026 --

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease Business Wire 8:00 AM

-- June 8, 2026 --

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase Business Wire 8:00 AM

-- May 27, 2026 --

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit Business Wire 8:00 AM

-- May 12, 2026 --

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Business Wire 7:35 AM

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Business Wire 7:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software